Recombinant Human Interleukin-2 (rHIL-2) Engineering Service

Recombinant Human Interleukin-2 (rHIL-2) is a critical cytokine used in cancer immunotherapy for activating T-cells and natural killer cells. While effective, large-scale production in Escherichia coli faces challenges: prokaryotic expression is prone to degradation due to host proteases and inclusion body formation, leading to low yield of active protein. Furthermore, the active form of native IL-2 often exhibits high toxicity (e.g., vascular leak syndrome) at therapeutic doses, limiting its clinical application. Biosynthesis offers a pathway for producing modified, less toxic forms with improved activity.

CD Biosynsis offers a synthetic biology service focused on engineering both the production system and the IL-2 protein structure itself for clinical advancement. Our core strategy involves modification of Escherichia coli secretion expression system . We utilize signal peptides and secretion pathways (e.g., Tat or Sec pathways) to direct the expression of rHIL-2 out of the reducing cytoplasm into the oxidizing periplasm or culture medium, improving correct disulfide bond formation and reducing proteolytic degradation. This is coupled with site-directed mutagenesis of protein structure . We introduce specific point mutations (e.g., modifying the Cys125 residue or mutations affecting the alpha receptor binding) to reduce binding affinity to the low-affinity receptor (CD25), thereby lowering systemic toxicity while maintaining high affinity for the therapeutic intermediate-affinity receptor (CD122/CD132). This integrated approach aims to deliver high yields of a safer, more stable, and selectively active rHIL-2 variant.

Pain Points

Efficient and safe rHIL-2 production faces these key technical and clinical challenges:

• Prokaryotic Expression is Prone to Degradation: High levels of proteases in the E. coli cytoplasm often cleave the rHIL-2 product , drastically reducing the yield of the full-length active protein.
• High Toxicity: Native IL-2 binds indiscriminately to all IL-2 receptor forms. Binding to the low-affinity IL-2Ralpha (CD25) on endothelial cells is believed to trigger severe vascular leak syndrome (VLS) , which is dose-limiting.
• Incorrect Folding and Aggregation: The E. coli cytoplasm is reducing, which hinders the formation of the essential intramolecular disulfide bond (Cys58-Cys105), leading to misfolded, inactive inclusion bodies.
• Low Solubility and Stability: The recombinant protein often exhibits poor stability in the culture medium and low solubility upon refolding, making downstream processing challenging.

A cost-effective solution requires minimizing proteolytic attack, ensuring correct folding, and optimizing the protein's receptor binding specificity.

Solutions

CD Biosynsis utilizes advanced expression system and protein engineering to optimize active rHIL-2 production in E. coli:

Modification of E. coli Secretion Expression System

           

We employ engineered E. coli Sec or Tat secretion systems and optimized signal peptides to transport rHIL-2 to the oxidizing periplasm or directly secrete it into the medium, promoting native folding.

Site-directed Mutagenesis of Protein Structure

We introduce specific mutations (e.g., CD25-attenuating mutations ) to create variants that preferentially activate CD122/CD132-positive cells while reducing binding to the low-affinity CD25 receptor, lowering toxicity .

Disulfide Bond Optimization and Stabilization

For native rHIL-2, we utilize host strains or protocols that favor the correct Cys58-Cys105 disulfide bond formation . For variants, we may mutate Cys125 to Ser (C125S) to prevent non-native dimerization.

Codon Optimization and Fusion Tag Strategy

We codon-optimize the gene for E. coli translation efficiency and may use a soluble fusion tag to enhance expression, followed by efficient tag removal.

This systematic approach addresses both the large-scale production bottleneck and the critical clinical toxicity issue simultaneously.

Advantages

Our rHIL-2 engineering service is dedicated to pursuing the following production goals:

Reduced Toxicity and Enhanced Safety

Mutagenesis minimizes binding to CD25, potentially eliminating dose-limiting VLS (Vascular Leak Syndrome) .

High Yield of Active Protein

Secretion and stabilization strategies reduce degradation and maximize the recovery of correctly folded, active rHIL-2.

Selective Immune Activation

Engineered variants preferentially stimulate effector T cells and NK cells over regulatory T cells (Tregs).

Cost-Effective E. coli Production

E. coli offers superior scalability and lower running costs compared to complex mammalian cell culture systems.

High Purity for Clinical Use

Optimized systems lead to a product with minimal aggregation and high homogeneity , suitable for therapeutic application.

We provide a specialized platform focused on developing next-generation, safer IL-2 therapeutics.

Process

Our rHIL-2 engineering service follows a rigorous, multi-stage research workflow:

• Gene Synthesis and Mutagenesis: Synthesize the rHIL-2 gene, including codon optimization and introduction of toxicity-reducing point mutations (e.g., Cys125Ser, or receptor-specific mutations).
• Secretion System Cloning: Clone the optimized gene into an E. coli vector equipped with a robust secretion signal peptide and optimized expression controls.
• Expression and Purification: Optimize induction and fermentation conditions to maximize the yield of active, secreted rHIL-2. Use affinity and ion-exchange chromatography for high-purity isolation .
• In Vitro Activity Assays: Perform cell proliferation assays (e.g., CTLL-2 cells) to confirm biological activity, and conduct receptor binding kinetics (e.g., SPR or Octet) to validate the desired CD25-attenuated binding profile.
• Stability and Purity Analysis: Analyze the final product using SDS-PAGE, Western Blot, and Mass Spectrometry to confirm purity, integrity, and lack of host contaminants.
• Result Report Output: Compile a detailed Experimental Report including strain data, purification protocols, and functional data (activity titer, binding affinity) , supporting clinical development.

Technical communication is maintained throughout the process, focusing on timely feedback regarding expression yield and functional activity.

Explore the potential for a safer, more effective rHIL-2 therapeutic. CD Biosynsis provides customized protein engineering solutions:

• Detailed Functional Activity and Specificity Report , demonstrating the improved therapeutic index (higher activity on CD122/CD132, lower activity on CD25).
• Consultation on optimized fermentation and purification protocols for cGMP compliance.
• Experimental reports include complete raw data on final active rHIL-2 titer (mg/L) and purity (%) , essential for clinical trials.